Full text is available at the source.
Abstract
Orforglipron led to weight reductions of more than 6 kg in patients with diabetes and nearly 12 kg in those without diabetes at the highest dose.
- Five randomized controlled trials involving 6140 participants were analyzed.
- Weight loss was dose-dependent, with greater reductions observed in individuals without diabetes.
- Significant improvements were noted in body mass index, waist circumference, and glycated hemoglobin (HbA1c) levels.
- Gastrointestinal adverse events were more common at higher doses.
- No significant difference in acute pancreatitis incidence was found.
Simplified